Drugging specific conformational states of GPCRs: Challenges and opportunities for computational chemistry

Drug Discovery Today

Volumn 21, Issue 4, 2016, Pages 625-631

  Martí Solano, Maria ^a   Schmidt, Denis ^b   Kolb, Peter ^b   Selent, Jana ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

DRUG TARGETING; MOLECULAR DOCKING; MOLECULAR STABILITY; PROTEIN CONFORMATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SIMULATION; CHEMISTRY; DRUG DESIGN; MOLECULAR DYNAMICS;

DRUG DESIGN; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84956677842     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.01.009     Document Type: Review

References (49)

1. V. Katritch, and et al. Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 53 2013 531 556
2. M. Audet, and M. Bouvier Restructuring G-protein-coupled receptor activation Cell 151 2012 14 23
3. G.M. West, and et al. Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX Structure 19 2011 1424 1432
4. R. Nygaard, and et al. The dynamic process of β2-adrenergic receptor activation Cell 152 2013 532 542
5. 19F-NMR Science 335 2012 1106 1110
6. M. Zocher, and et al. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor Structure 20 2012 1391 1402
7. C. Altenbach, and et al. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation Proc. Natl. Acad. Sci. U. S. A. 105 2008 7439 7444
8. A.M. Preininger, and et al. Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: a perspective J. Mol. Biol. 425 2013 2288 2298
9. J. Urban, and et al. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320 2007 1 13
10. P.S.H. Park Ensemble of G protein-coupled receptor active states Curr. Med. Chem. 19 2012 1146 1154
11. H.O. Onaran, and T. Costa Where have all the active receptor states gone? Nat. Chem. Biol. 8 2012 674 677
12. E.J. Whalen, and et al. Therapeutic potential of β-arrestin- and G protein-biased agonists Trends Mol. Med. 17 2011 126 139
13. M. Martí-Solano, and et al. Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design Curr. Pharm. Des. 19 2013 5156 5166
14. J.W. Wisler, and et al. Recent developments in biased agonism Curr. Opin. Cell Biol. 27C 2014 18 24
15. J.D. Violin, and et al. Biased ligands at G-protein-coupled receptors: promise and progress Trends Pharmacol. Sci. 35 2014 308 316
16. J.D. Violin, and et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance J. Pharmacol. Exp. Ther. 335 2010 572 579
17. K.L. White, and et al. The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo J. Pharmacol. Exp. Ther. 352 2015 98 109
18. X. Liu, and et al. β-Arrestin-biased signaling mediates memory reconsolidation Proc. Natl. Acad. Sci. U. S. A. 112 2015 E2847
19. C.J. Langmead, and A. Christopoulos Functional and structural perspectives on allosteric modulation of GPCRs Curr. Opin. Cell Biol. 27 2014 94 101
20. J.R. Lane, and et al. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 34 2013 59 66
21. C. Valant, and et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist Proc. Natl. Acad. Sci. U. S. A. 111 2014 4614 4619
22. R.O. Dror, and et al. Activation mechanism of the β2-adrenergic receptor Proc. Natl. Acad. Sci. U. S. A. 108 2011 18684 18689
23. D. Shaw, and et al. Anton, a special-purpose machine for molecular dynamics simulation Commun. ACM 51 2008 91 97
24. K.J. Kohlhoff, and et al. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways Nat. Chem. 6 2013 15 21
25. J.L. Hellerstein Science in the cloud: accelerating discovery in the 21st century IEEE Internet Comput. 16 2012 64 68
26. A. Rose, and et al. Position of transmembrane helix 6 determines receptor G protein coupling specificity J. Am. Chem. Soc. 136 2014 11244 11247
27. M. Marti-Solano, and et al. A dynamic view of molecular switch behavior at serotonin receptors: implications for functional selectivity PLoS One 9 2014 e109312
28. W. Huang, and et al. Structural insights into μ-opioid receptor activation Nature 524 2015 315 321
29. S. Yuan, and et al. The mechanism of ligand-induced activation or inhibition of μ- and κ-opioid receptors Angew. Chem. Int. Ed. Engl. 1207 2015 1 5
30. S. Yuan, and et al. Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway Nat. Commun. 5 2014 4733
31. V. Katritch, and et al. Structure based prediction of subtype-selectivity for adenosine receptor antagonists Neuropharmacology 60 2011 108 115
32. P. Kolb, and et al. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists PLoS One 7 2012 e49910
33. A. Negri, and et al. Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening J. Chem. Inf. Model. 53 2013 521 526
34. A. Kruse, and et al. Muscarinic receptors as model targets and antitargets for structure-based ligand discovery Mol. Pharmacol. 84 2013 528 540
35. D. Rodríguez, and et al. Structure-based discovery of selective serotonin 5-HT1B receptor ligands Structure 22 2014 1140 1151
36. D. Schmidt, and et al. Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking ACS Chem. Biol. 10 2015 715 724
37. D.R. Weiss, and et al. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor ACS Chem. Biol. 8 2013 1018 1026
38. D. Rodríguez, and et al. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor J. Chem. Inf. Model. 55 2015 550 563
39. I. Kufareva, and et al. Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges Structure 22 2014 1 20
40. D. Wacker, and et al. Structural features for functional selectivity at serotonin receptors Science 469 2013 175 180
41. A.J. Kooistra, and et al. Structure-based prediction of G-protein-coupled receptor ligand function: a β-adrenoceptor case study J. Chem. Inf. Model. 55 2015 1045 1061
42. M. Marti-Solano, and et al. Detection of new biased agonists for the serotonin 5-HT2A receptor: modeling and experimental validation Mol. Pharmacol. 87 2015 740 746
43. G. Liapakis, and et al. The G-protein coupled receptor family: actors with many faces Curr. Pharm. Des. 18 2012 175 185
44. J. Sallander, and et al. Structural determinants of subtype selectivity and functional activity of angiotensin II receptors Bioorg. Med. Chem. Lett. 2015 10.1016/j.bmcl.2015.10.084
45. I.S. Moreira Structural features of the G-protein/GPCR interactions Biochim. Biophys. Acta 1840 2014 16 33
46. T. Okada, and et al. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure J. Mol. Biol. 342 2004 571 583
47. H-W. Choe, and et al. Crystal structure of metarhodopsin II Nature 471 2011 651 655
48. Y. Kang, and et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser Nature 523 2015 561 567
49. M. Bellot, and et al. Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling Nat. Chem. Biol. 11 2015 271 279